BIO

Chariya Peeyatu obtained a Bachelor’s degree in Biochemistry from Chulalongkorn University, Thailand, in 2017. During her undergraduate studies, she worked on enzyme and metabolic engineering to produce an industrially important intermediate via microbial cell factories. She also completed a bio-fermentation internship at Yamaguchi University, Japan. In 2021, she completed an MSc in Biomedical Engineering at Prince of Songkla University, Thailand. Her master’s thesis focused on the structural analysis of engineered interleukin-18 using molecular dynamics simulations, with the aim of enhancing protein stability for use as a biologic in cancer therapy.

From 2021 to 2023, Chariya worked as a research assistant at the National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand. Her research involved drug screening of proteolysis-targeting chimeras (PROTACs) as potential antimalarial agents. This project was conducted in collaboration with FIMECS, Inc., a Japanese biopharmaceutical startup developing a platform for discovering novel E3 ligase binders.

In September 2023, Chariya transitioned her research focus to drug delivery systems by pursuing an MSc by Research in Nanomedicine at the University of Manchester (UoM). The MSc project aimed to understand liposome translocation across the blood-brain barrier of post-resection glioblastoma using mouse brain sections. Supported by a postgraduate scholarship from the Royal Thai Government, she commenced her PhD in January 2025 at the Nanotherapeutics Lab, Centre for Nanotechnology in Medicine, UoM. Her doctoral research focuses on developing targeted lipid-based drug delivery systems for postoperative glioblastoma therapy and is conducted in collaboration with the Nanomedicine Lab at ICN2.